Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 5/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456727 | 0.68 | — | — | |
| SCHEMBL8407756 | 0.68 | CYP1A2 (0.41) | CYP1A2TMIGD3CYP2C9ADORA1ADORA2A | |
| SCHEMBL256090 | 0.67 | — | — | |
| SCHEMBL7857005 | 0.67 | — | — | |
| SCHEMBL8577387 | 0.67 | — | — | |
| SCHEMBL26754441 | 0.67 | GABRR1 (0.41) | CYP1A2TMIGD3CYP2C9ADORA1ADORA2A | |
| SCHEMBL1886662 | 0.66 | — | — | |
| SCHEMBL7348065 | 0.64 | PAK1 (0.36) | — | |
| SCHEMBL15782808 | 0.64 | HSD17B10 (0.47) | HCAR2CYP2C19HSD17B10GABRR1PDE4A | |
| SCHEMBL7354669 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-8796283-B2 | Indole and azaindole modulators of the alpha 7 nachr | PROXIMAGEN LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| EP-2488514-B1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LTD (GB) | 2013-12-25 | — | — | EP | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| WO-2009024214-A1 | PROCESS FOR THE PRODUCTION OF VORICONAZOLE | AXELLIA PHARMACEUTICALS APS (DK) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | CHRNA7, CHRNA5, CHRNA1 | HCAR2 215/4885CYP1A2 711/4885TMIGD3 3942/4885 |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | CHRNA7, CHRNA5, CHRNA1 | HCAR2 209/4885CYP1A2 758/4885TMIGD3 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.